Advances in critical care hepatology

Minerva Anestesiologica

Volumn 72, Issue 5, 2006, Pages 269-281

  Volk, M L ^a,b   Marrero, J A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Critical care; Hepatology; Liver

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACETYLCYSTEINE; ALBUMIN; AMMONIUM CHLORIDE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEPHALOSPORIN; CIPROFLOXACIN; DIAZEPAM; DIURETIC AGENT; FRESH FROZEN PLASMA; GLUCAGON; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; LACTULOSE; MANNITOL; METRONIDAZOLE; MIDODRINE; OCTREOTIDE; PARACETAMOL; PENICILLIN G; PENTOBARBITAL; QUINOLONE DERIVATIVE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SOMATOSTATIN; TERLIPRESSIN; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN; VITAMIN K GROUP;

ABDOMINAL CRAMP; ANTIBACTERIAL ACTIVITY; ASCITES; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BLOATING; BLOOD CLOTTING DISORDER; BOLUS INJECTION; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; ESOPHAGUS VARICES BLEEDING; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HISTOPATHOLOGY; HORMONE INHIBITION; HUMAN; HYPOGLYCEMIA; HYPOTHERMIA; INTENSIVE CARE; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE MONITORING; ISCHEMIA; LABORATORY TEST; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; REVIEW; SODIUM RESTRICTION; SUPERINFECTION; THROMBOCYTE TRANSFUSION;

ASCITES; CASE MANAGEMENT; CRITICAL CARE; DISEASE PROGRESSION; ESOPHAGEAL AND GASTRIC VARICES; GASTROENTEROLOGY; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGIC DISORDERS; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LIVER DISEASES; LIVER FAILURE, ACUTE; PERITONITIS;

EID: 33646841181     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Aggarwal A, Ong JP, Younossi ZM, Nelson DR, Hoffman-Hogg L, Arroliga AC. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 2001;119:1489-97.
2. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273-5.
3. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54.
4. Bismuth H, Samuel D, Castaing D, Williams R, Pereira SP. Liver transplantation in Europe for patients with acute liver failure. Semin Liver Dis 1996;16:415-25.
5. Mas A, Rodes J. Fulminant hepatic failure. Lancet 1997; 349:1081-5.
6. Rolando N, Gimson A, Wade J, Philpott-Howard J, Casewell M, Williams R. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology 1993;17:196-201.
7. Schiodt FV, Bondesen S, Tygstrup N, Christensen E. Prediction of hepatic encephalopathy in paracetamol overdose: a prospective and validated study. Scand J Gastroenterol 1999;34:723-8.
8. Zimmerman JL. Poisonings and overdoses in the intensive care unit: general and specific management issues. Crit Care Med 2003;31:2794-801.
9. Harrison PM, Keays R, Bray GP, Alexander GJ, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990;335:1572-3.
10. Shakil AO, Mazariegos GV, Kramer DJ. Fulminant hepatic failure. Surg Clin North Am 1999;79:77-108.
11. Munoz SJ, Moritz MJ, Martin P, Westerberg S, Northrup B, Bell R et al. Relationship between cerebral perfusion pressure and systemic hemodynamics in fulminant hepatic failure. Transplant Proc 1993;25:1776-8.
12. Munoz SJ, Robinson M, Northrup B, Bell R, Moritz M, Jarrell B et al. Elevated intracranial pressure and computed tomography of the brain in fulminant hepatocellular failure. Hepatology 1991;13:209-12.
13. Lidofsky SD, Bass NM, Prager MC, Washington DE, Read AE, Wright TL et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 1992;16:1-7.
14. Jalan R, Olde Damink SW, Deutz NE, Davies NA, Garden OJ, Madhavan KK et al. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure. Transplantation 2003;75: 2034-9.
15. Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003;9:138-43.
16. Pavese P, Bonadona A, Beaubien J, Labrecque P, Pernod G, Letoublon C et al. FVIIA corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 2005;52:26-9.
17. McCashland TM, Shaw BW Jr, Tape E. The American experience with transplantation for acute liver failure. Semin Liver Dis 1996;16:427-33.
18. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
19. Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-7; discussion 667-70.
20. Robbins KC. Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier; 2005.
21. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985;1:325-37.
22. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28:926-31.
23. Atucha NM, Shah V, Garcia-Cardena G, Sessa WE, Groszmann RJ. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology 1996;111:1627-32.
24. Gines P, Fernandez-Esparrach G, Arroyo V, Rodes J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997;17:175-89.
25. Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-502.
26. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2oo4;40:629-35.
27. Alessandria C, Gaia S, Marzano A, Venon WD, Fadda M, Rizzetto M. Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol 2004;16:607-12.
28. Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol 2002;13:385-90.
29. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
30. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23: 164-76.
31. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-6.
32. Esrailian E. Octreotide/midodrine therapy significantly improves survival in Type 1 hepatorenal syndrome: analysis of 53 treated patients and 21 controls. Gastroenterology 2003;124:A718.
33. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
34. Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Buttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995;17:135-46.
35. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001;120:726-48.
36. Garcia-Tsao G. Spontaneous bacterial peritonitis. Gastroenterol Clin North Am 1992;21:257-75.
37. Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis 1998;27:669-74; quiz 675-6.
38. Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis - in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol 2001;96:1232-6.
39. Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991;100:1737-42.
40. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.
41. Navasa M, Follo A, Filella X, Jimenez W, Francitorra A, Planas R et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227-32.
42. Soares-Weiser K, Brezis M, Tur-Kaspa R, Paul M, Yahav J, Leibovici L. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. Scand J Gastroenterol 2003;38:193-200.
43. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controfled trial. Hepatology 1990;12(4 Pt 1):716-24.
44. Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22(4 Pt 1):1171-4.
45. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-7.
46. Grace ND. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am 1992;21:149-61.
47. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-9.
48. Kravetz D, Bosch J, Arderiu M, Pilar Pizcueta M, Rodes J. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. Hepatology 1989;9: 808-14.
49. Soriano G, Guarner C, Tomas A, Villanueva C, Torras X, Gonzalez D et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992;103:1267-72.
50. Comar KM, Sanyal AJ. Portal hypertensive bleeding. Gastroenterol Clin North Am 2003;32:1079-105.
51. Conn HO. Vasopressin and nitroglycerin in the treatment of bleeding varices: the bottom line. Hepatology 1986;6:523-5.
52. Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. Lancet 1982;2:66-8.
53. Burroughs AK. Octreotide in variceal bleeding. Gut 1994;35(3 Suppl):S23-7.
54. Kravetz D, Bosch J, Teres J, Bruix J, Rimola A, Rodes J. Comparison of intravenous somatostatin and vasopressin infusions in treaunent of acute variceal hemorrhage. Hepatology 1984;4:442-6.
55. Pedretti G, Elia G, Calzetti C, Magnani G, Fiaccadori F. Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin Investig 1994;72: 653-9.
56. Stiegmann GV, Goff JS, Sun JH, Wilborn S. Endoscopic elastic band ligation for active variceal hemorrhage. Am Surg 1989;55:124-8.
57. Patch D, Sabin CA, Goulis J, Gerunda G, Greenslade L, Merkel C et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002;123:1013-9.
58. LaBerge JM, Ring EJ, Gordon RL, Lake JR, Doherty MM, Somberg KA et al. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 1993;187: 413-20.
59. Greene C. Liver and bilary tract; review for 1940. Arch Intern Med 1941;67:867-98.
60. Sherlock S. Portal-systemic encephalopathy: neurologic complications of liver disease. Lancet 1954: 453-7.
61. Frerichs F. Clinical Treatise on Diseases of the Liver. London: New Sydenham Society; 1861.
62. Hahn M. Die Ecksche Fistel zqischen der unteren Hohlvene und der Pfortader und ihre Folgen Fur den Organismus. Arch Exp Path Pharmakol 1893;32: 161-70.
63. Rodwell V. Catabolism of proteins and of amino acid nitrogen. Stamford, CN: Appleton and Lange; 1996.
64. Weber FL Jr, Veach GL. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology 1979;77:235-40.
65. Vince A, Zeegen R, Drinkwater JE, O'Grady F, Dawson AM. The effect of lactulose on the faecal flora of patients with hepatic encephalopathy. J Med Microbiol 1974;7:163-8.
66. Gazbuda D. Reversible toxic manifestations in patients with cirrhosis of the liver given cation-exchange resins. N Engl J Med 1952;246:124-30.
67. Hsia YE. Inherited hyperammonemic syndromes. Gastroenterology 1974;67:347-74.
68. Luca A, D'Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology 1999;212:411-21.
69. Stahl J. Studies of the blood ammonia in liver disease. Its diagnostic, prognostic, and therapeutic significance. Ann Intern Med 1963;58:1-24.
70. Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997;25: 1303-5.
71. Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology 1996;23:1041-6.
72. Blei AT, Cordoba J. Hepatic Encephalopathy. Am J Gastroenterol 2001;96:1068-76.
73. Simmons F, Goldstein H, Boyle JD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 1970;59:827-32.
74. Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N Engl J Med 1969;281: 408-12.
75. Germain L, Frexinos J, Louis A, Ribet A. [Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt]. Arch Fr Mal App Dig 1973;62:293-302.
76. Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992;39:542-5.
77. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Gortelmeyer R et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998;28:856-64.
78. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G et al. Flumazenil for hepatic encephalopathy grude III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998;28:374-8.
79. Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991;100:1114-8.
80. Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991;36:1204-8.
81. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-21.